Prof. Dr. med. Carola Berking

Lehrstuhl für Haut- und Geschlechtskrankheiten

Occlusive cutaneous vasculopathies as cause of chronic ulcers (2024) Ronicke M, Berking C, Erfurt-Berge C Journal article European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes) (2024) Kandolf L, Peris K, Malvehy J, Mosterd K, Heppt M, Fargnoli MC, Berking C, et al. Journal article Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. (2024) Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, et al. Journal article S3 guideline „actinic keratosis and cutaneous squamous cell carcinoma“ – update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention (2023) Leiter U, Heppt M, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, et al. Journal article S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma"- update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care (2023) Heppt M, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, et al. Journal article S3-Leitlinie “Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Update 2023, Teil 1: Therapie der aktinischen Keratose, Morbus Bowen, Cheilitis actinica, berufsbedingte Erkrankung und Versorgungsstrukturen (2023) Heppt M, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, et al. Journal article Threshold Optimization for Tumor Markers S100b and MIA in Uveal Melanoma - A Single Center Analysis (2023) Glaser N, Petzold A, Wessely A, Kaufmann M, Koch E, Knorr H, Voskens C, et al. Journal article Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG (2023) Haist M, Stege H, Rogall F, Tan Y, von Wasielewski I, Klespe KC, Meier F, et al. Journal article Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp (2023) Hassel JC, Berking C, Forschner A, Gebhardt C, Heinzerling L, Meier F, Ochsenreither S, et al. Journal article Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study (2023) Lodde GC, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, Hauschild A, et al. Journal article